Startup Triomics Gets Funding to Expand Oncology AI Platform

An oncology AI startup called Triomics has announced Series B funding as its customer base has grown to include cancer centers such as Memorial Sloan Kettering Cancer Center (MSK), MD Anderson, Yale Cancer Center and its partner Smilow Cancer Hospital, and Mount Sinai Tisch Cancer Center, as well as some of the nation's largest community oncology practices, such as Texas Oncology. 

Cancer centers use the platform to expand trial access, reduce the burden of manual chart review, improve visit preparation and generate higher‑quality structured data for research and operations.

Founded in 2021, Triomics says it is building a platform that uses AI agents to read the full longitudinal patient record and converts unstructured information into structured, explainable outputs. Then it delivers those insights directly into clinical and operational workflows. Unlike lightweight summarization tools, every output is source-backed and verifiable inside the clinician's workflow, the company says. The platform supports proactive clinical trial matching, pre-visit chart review and preparation, and oncology data abstraction for registry, quality improvement and operational use cases.

Triomics has raised $22 million in Series B financing led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed and Y Combinator, alongside strategic backers Oncology Ventures and Precision Health Informatics, a wholly-owned subsidiary of Texas Oncology. This round brings Triomics' total funding raised to date to more than $36 million.

"Oncology is the hardest place to build AI, yet the most important," said Hrituraj Singh, co-founder and CTO of Triomics, in a statement. "Getting a model to reason reliably across thousands of pages of notes, pathology, imaging and evolving trial criteria, and show its work, is what separates a demo from software that clinicians actually use. We've spent four years building that foundation and this round lets us push even further."

In a prepared statement, Lee Schwamm, M.D., chief digital health officer, Yale New Haven Health System, and associate dean, Digital Strategy & Transformation, Yale School of Medicine, explained the value his organization sees in the partnership. "We are excited to partner with Triomics, our selected solution for oncology clinical trial matching, to extend our collaboration to an AI-enabled method for cancer registry abstraction and reporting,” he said. “This activity is labor-intensive, subjective and challenging to complete in a timely manner. Our goal is to produce autonomous chart abstraction of clinical registry quality that can be rapidly reviewed and finalized for reporting by human registrars to comply with mandatory state, federal and professional society reporting obligations.”